OptimizeRx announces stock sale

ROCHESTER — OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital health messaging for the pharmaceutical industry, announced a proposed underwritten public offering by a current shareholder, WPP Luxembourg Gamma Three S.à r.l., of 2,103,702 shares of OptimizeRx common stock.

In connection with this offering, OptimizeRx expects to grant the underwriters a 30-day option to purchase up to an additional 315,555 newly issued shares of common stock from the company at the public offering price less the underwriting discount and commissions.

OptimizeRx will not receive any proceeds from the sale of the shares by the selling shareholder, but would receive the proceeds of the underwriters’ option of 315,555 additional shares, if the option is exercised.

The shares of common stock described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-228357) that was originally filed with the Securities and Exchange Commission Nov. 13 and declared effective by the SEC Dec. 11.

A preliminary prospectus supplement and accompanying base prospectus relating to the offering and the shares of common stock being offered will be filed with the SEC. Copies of the registration statement, the preliminary prospectus supplement and accompanying base prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606; Phone: (800) 621-0687; Email: prospectus@williamblair.com; and from B. Riley FBR, Inc., Attention: Syndicate Prospectus Department, 1400 North 17th Street, Suite 1300, Arlington, VA 22209; Phone: (703) 312-9580; Email: prospectuses@brileyfbr.com.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.